Saphnelo (anifrolumab-fnia) — HCPCS J0491

First-in-class mechanism — type I interferon receptor antagonist FDA verified Apr 2026

Saphnelo is the only approved drug that blocks the IFN-α/β receptor — mechanistically distinct from every other lupus biologic.

Anifrolumab-fnia is a fully human IgG1κ monoclonal antibody that binds subunit 1 of the type I interferon receptor (IFNAR1). By blocking IFNAR1, Saphnelo prevents signaling from all type I interferons: IFN-α (13 subtypes), IFN-β, IFN-ω, and IFN-κ. Type I IFN over-activity ("IFN signature") is a central driver of SLE pathophysiology in approximately 60–80% of patients.

Why this matters for billing & PA

• Distinct mechanism from B-cell-targeting biologics — not a step therapy substitute for Benlysta or Rituxan
• Most payers do not require IFN-signature testing for PA approval (no companion diagnostic), unlike PD-L1 for ICIs
• Some payers will allow patients who failed Benlysta to step to Saphnelo and vice-versa (parallel options, not sequential)
• Combination with another biologic (Benlysta, Rituxan) is NOT recommended per FDA label and ACR guidance

Lupus biologic class comparison ACR/EULAR + FDA labels Apr 2026

Saphnelo and Benlysta are both first-line biologics. Choice depends on disease phenotype, especially LN involvement.

Dosing & unit math FDA label Apr 2026

Fixed dose, no titration. Same 300 mg every 4 weeks for every adult patient.

Adult dosing — fixed (NOT weight-based)

• 300 mg IV every 4 weeks (fixed dose for all adults regardless of weight)
• No loading dose; first dose = 300 mg, then 300 mg q4w
• 30-minute infusion time; dilute in 100 mL 0.9% NaCl
• One 300 mg / 2 mL single-dose vial per dose — no waste expected
• 1 mg = 1 unit — bill 300 units per dose
• 13 doses/year typical (q4w × 52 weeks)

Pediatric — not approved

Saphnelo's safety and effectiveness in pediatric SLE patients (<18 years) have not been established. Pediatric SLE patients requiring biologic therapy should consider Benlysta (FDA-approved for SLE patients ages 5 and older).

Worked example — first-year billing for a typical SLE patient

Premedication & monitoring

Routine premedication is not required. The FDA label recommends an observation period for the first dose to monitor for hypersensitivity. Subsequent doses can be administered without extended post-infusion monitoring unless a prior reaction occurred. Live vaccines should be avoided before, during, and shortly after Saphnelo therapy due to immunosuppression risk.

NDC reference FDA NDC Directory verified May 2026

Administration codes CPT verified May 2026

Saphnelo is non-chemotherapy. Use therapeutic IV codes, not chemo admin codes.

Modifiers CMS verified May 2026

JZ — required on virtually every Saphnelo claim

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded. The Saphnelo 300 mg dose uses exactly one 300 mg single-dose vial — the dose matches the vial size precisely, so no waste is expected. JZ applies to virtually every Saphnelo claim.

JW — rare for Saphnelo

JW reports the discarded portion of a single-dose vial. Because Saphnelo's fixed 300 mg dose matches the 300 mg vial exactly, partial-vial waste is uncommon. The only realistic JW scenario is mid-infusion discontinuation (hypersensitivity reaction, infusion reaction) before the full 300 mg has been delivered — in that case, bill JZ on the units administered and JW on the discarded units, on separate claim lines. One of JZ or JW must be on every J0491 claim.

Modifier 25 — same-day E/M

Use modifier 25 on the E/M code when a significant, separately identifiable evaluation and management service is performed on the same day as the infusion (e.g., rheumatology disease-activity assessment). Routine pre-infusion clinical assessment is bundled.

340B modifiers (JG, TB)

For 340B-acquired Saphnelo, follow your MAC's current 340B modifier policy. AstraZeneca's billing materials do not provide 340B-specific instructions.

ICD-10-CM — M32.x SLE family FY2026 verified May 2026

Use the most specific code supported by encounter documentation. Active LN codes are exclusion criteria, not approval pathway.

Lupus nephritis exclusion — the hard wall FDA + Payer policies May 2026

This is the #1 reason for Saphnelo PA denial. Understand it cold before submitting.

Saphnelo's FDA label states: "The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations." This is more than label language — it's enforced by every major commercial payer and Medicare LCDs.

Why the exclusion exists

• Phase 3 TULIP-1 and TULIP-2 trials excluded patients with active LN (UPCR > 2.0 g/g, recent renal flare)
• The dedicated TULIP-LN phase 3 trial in active LN did NOT meet primary endpoints
• FDA approved the SLE indication only, with explicit LN exclusion language

What payers enforce

• UnitedHealthcare: PA criteria require absence of active LN documented within 6 months (recent UPCR/UA, GFR)
• Aetna: Saphnelo medical drug policy explicitly excludes active LN; requires nephrology consult if any history of LN
• BCBS plans: Most align with FDA label exclusion language
• Medicare LCDs: Cover for label indication (moderate-severe SLE without active LN)

What to do for SLE + LN patients

Submit PA for Benlysta (J0490 belimumab) instead. Benlysta has separate FDA-approved indications for both SLE and active lupus nephritis (added December 2020), making it the appropriate biologic when LN is part of the disease picture. Lupkynis (voclosporin oral) is also approved for active LN as add-on to background MMF + steroids.

Site of care & place of service Verified May 2026

UnitedHealthcare and Aetna both run site-of-care UM for non-oncology infusions. Saphnelo is steered toward office-based and ambulatory infusion settings; HOPD administration is disfavored after the first few doses unless clinically justified.

Claim form field mapping AZ Access 360 2026

Standard CMS-1500 / 837P drug + admin line layout.

Payer policy snapshot Reviewed May 2026

All major payers require PA + standard-therapy failure documentation + LN exclusion confirmation.

Standard-therapy failure documentation checklist

• Hydroxychloroquine (HCQ): current use OR documented intolerance/retinopathy; required for nearly all SLE patients per ACR/EULAR
• Corticosteroids: trial of moderate-to-high dose (e.g., prednisone ≥7.5 mg/day) with attempted taper documented
• DMARD/immunosuppressant: at least one of methotrexate, mycophenolate mofetil, azathioprine; documented failure or intolerance
• Active disease evidence: SLEDAI-2K score, BILAG flare grade, or equivalent disease-activity instrument
• Rheumatology consult: required by UHC and Aetna; specialist note recommending Saphnelo
• LN exclusion: renal labs within 6 months (UPCR < 2.0 g/g, no active sediment) OR explicit nephrology statement of "no active LN"

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.

Coverage

No NCD specific to anifrolumab. Coverage falls under MAC LCDs for biologics + the generic drug-coverage framework. All MACs cover J0491 for FDA-approved on-label indications (moderate-to-severe SLE, no active LN) with appropriate ICD-10 documentation.

Code history

• August 2, 2021 — FDA approval (BLA 761123); pre-permanent-code period used unclassified J3490 with NDC documentation
• July 1, 2022 – Dec 31, 2022 — temporary HCPCS C9085 for hospital outpatient billing
• January 1, 2023 — permanent HCPCS J0491 assigned ("Inj anifrolumab-fnia 1mg")

Patient assistance — AstraZeneca Access 360 AZ verified May 2026

• AZ Access 360 / Saphnelo Co-pay Program: 1-844-275-2360 / saphnelo.com — benefits investigation, prior authorization assistance, appeal support
• Saphnelo Co-pay Program (commercial): $0 first dose for eligible commercially-insured patients; ongoing copay support up to $20,000/year (excludes Medicare, Medicaid, federal program patients)
• AZ Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements (administered through AstraZeneca Patient Savings Program / AZ&MeRx)
• Foundations for Medicare: for Medicare patients, refer to PAN, HealthWell, Patient Advocate Foundation lupus funds — verify open lupus funds quarterly (lupus-specific funds open intermittently)
• Web: saphnelo.com / myazcareconnect.com (AZ Access 360 portal)

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Saphnelo?

Saphnelo (anifrolumab-fnia IV) is billed under HCPCS J0491 — "Injection, anifrolumab-fnia, 1 mg." Each milligram equals one billable unit, so the standard 300 mg q4wk fixed dose is billed as 300 units. J0491 became permanent on January 1, 2023 (replacing the prior temporary C9085 / unclassified J3490 pathway used after the August 2021 FDA approval).

How many units do I bill for a Saphnelo dose?

Bill 300 units of J0491 per dose. Saphnelo is fixed-dose (NOT weight-based) at 300 mg IV every 4 weeks. One 300 mg single-dose vial per infusion, no waste expected. Annual billing: 13 doses × 300 units = 3,900 units per year.

What administration CPT do I use for Saphnelo?

Saphnelo is a non-chemotherapy therapeutic IV monoclonal antibody. Bill CPT 96365 — "Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour" — as the primary admin code. Saphnelo is infused over 30 minutes, fitting within 96365's 1-hour window. Add 96366 only if the infusion or other concurrent infusions extend beyond the first hour. Do NOT bill chemo admin codes (96413/96415).

Do I bill JZ or JW for Saphnelo?

Bill JZ on virtually every Saphnelo claim. The 300 mg dose uses exactly one 300 mg single-dose vial with no expected waste. JW is rare for Saphnelo because the dose matches the vial size precisely; the only typical waste scenario is mid-infusion discontinuation due to a hypersensitivity reaction. One of JZ or JW must be on every J0491 claim per CMS's July 2023 single-dose container policy.

What is the Medicare reimbursement for J0491?

For Q2 2026, the Medicare Part B payment limit for J0491 is $18.307 per mg (ASP + 6%). The 300 mg q4w dose reimburses at approximately $5,492.10 per infusion. Annualized cost (Medicare ASP+6%) for 13 doses per year is approximately $71,397. Sequestration (~2%) reduces actual paid to roughly ASP + 4.3%. ASP is updated quarterly by CMS.

Is Saphnelo approved for lupus nephritis?

No. Saphnelo's FDA label specifically excludes patients with severe active lupus nephritis. Phase 3 trials of anifrolumab in active LN (TULIP-LN) did not meet primary endpoints, and the FDA-approved indication is limited to moderate-to-severe SLE in adults receiving standard therapy who do NOT have active LN or active CNS lupus. For SLE patients with concurrent active lupus nephritis, Benlysta (J0490 belimumab) is the appropriate biologic — it has a separate FDA-approved LN indication added December 2020 that Saphnelo does not.

How does Saphnelo's mechanism differ from Benlysta?

Saphnelo is a first-in-class type I interferon receptor (IFNAR1) antagonist — it binds the IFN-α/β receptor and blocks signaling from all type I interferons (IFN-α, IFN-β, IFN-ω, IFN-κ). Type I IFN dysregulation is a central driver of SLE pathophysiology in ~60-80% of patients. Benlysta (belimumab) targets B-cell activating factor (BAFF/BLyS), reducing autoreactive B-cell survival. Different mechanisms, different patient profiles — and they are not currently studied or recommended in combination.

What standard therapy must a patient fail before Saphnelo coverage?

Major commercial payers require documented failure or intolerance of: (1) hydroxychloroquine (HCQ) or chloroquine — required for nearly all SLE patients per ACR/EULAR; (2) corticosteroids (typically a trial of moderate-to-high dose with attempted taper); and (3) at least one conventional DMARD or immunosuppressant — methotrexate, mycophenolate mofetil, azathioprine, or similar. Rheumatology consultation note is required by UHC and Aetna. Saphnelo is added on top of standard therapy, not as a replacement.

Source documents

1. AstraZeneca Access 360 — Saphnelo HCP coding & coverage
   AZ Access 360 2026 reimbursement guide (updated 2026)
2. DailyMed — SAPHNELO (anifrolumab-fnia) Prescribing Information
   FDA-approved label, BLA 761123 (initial approval August 2021)
3. FDA Saphnelo label PDF (initial approval 2021)
4. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file, effective April 1 – June 30, 2026
5. SEER CanMED — HCPCS J0491 reference
6. UnitedHealthcare — Saphnelo Medical Drug policy
7. Aetna — Anifrolumab medical drug policy
8. ACR — SLE Management Guidelines
   American College of Rheumatology guidelines for systemic lupus erythematosus
9. EULAR — SLE management recommendations
   European Alliance of Associations for Rheumatology recommendations
10. Saphnelo HCP and patient site (AstraZeneca)
11. FDA National Drug Code Directory

About this page

We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.

Found an error? Email hello@carecostestimate.com.

Refresh cadence

Reviewer

Change log

• May 2, 2026 — Initial publication. ASP data: Q2 2026 ($18.307/mg). Manufacturer source: AZ Access 360 2026. FDA label: BLA 761123, initial approval Aug 2021. First-in-class IFNAR1 antagonist context, lupus biologic class comparison, and lupus nephritis exclusion documented.

Methodology

Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Mechanism and class-comparison content is verified against the FDA label, ACR/EULAR guidance, and peer-reviewed pivotal trial publications (TULIP-1, TULIP-2). We do not paraphrase from billing-software vendor blogs.